Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Two posters on tacicepts caught our eyes. First is the Tumlin publication on povetacicept, an oral presentation in the “Late-Breaking Research” session. This is an interim look at Phase 1b study data reporting on 17 IgAN patients treated for 48 weeks with a dose of 80 mg and 30 patients Continue reading TACICEPTS VYING FOR YOUR ATTENTION
Companies can stop studies before reaching projected enrollment numbers. It could be a decision based on a planned interim analysis (IA) or it could be for ‘administrative’ reasons. The latter may not indicate that a company has fallen on hard times financially; it could be the result of operational problems Continue reading THE UTILITY OF FUTILITY